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Mechanism of Activation of the RAF-ERK Signaling
Pathway by Oncogenic Mutations of B-RAF
(Robinson and Cobb, 1997). The transforming activities
of the viral oncogenic forms of RAS and RAF were key
to their discovery (Rapp et al., 1983), and RAF was the
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Constitutive activation of the RAS-ERK signaling path-
way is common to numerous cancers. Approximately
15% of human cancers have activating RAS mutationsSummary
(Malumbres and Barbacid, 2003), and recently muta-
tions in B-RAF were identified in a large-scale screenOver 30 mutations of the B-RAF gene associated with
for genes mutated in human cancer (Davies et al., 2002).human cancers have been identified, the majority of
Somatic mutations of B-RAF are associated with 60%which are located within the kinase domain. Here
of malignant melanomas and occur with moderate towe show that of 22 B-RAF mutants analyzed, 18 have
high frequency in colorectal (Rajagopalan et al., 2002),elevated kinase activity and signal to ERK in vivo. Sur-
ovarian (Singer et al., 2003), and papillary thyroid carci-prisingly, three mutants have reduced kinase activity
nomas (Brose et al., 2002; Cohen et al., 2003), implicat-towards MEK in vitro but, by activating C-RAF in vivo,
ing activating oncogenic mutations of B-RAF as critical
signal to ERK in cells. The structures of wild type and
promoters of malignancy. Significantly, B-RAF and RAS
oncogenic V599EB-RAF kinase domains in complex with
mutations are restricted to the same tumor types,
the RAF inhibitor BAY43-9006 show that the activation usually in a mutually exclusive fashion, suggesting that
segment is held in an inactive conformation by associ- these genes are on the same oncogenic signaling path-
ation with the P loop. The clustering of most muta- way and that RAS acts to activate B-RAF in these
tions to these two regions suggests that disruption of tumors.
this interaction converts B-RAF into its active confor- Sequence analysis of the B-RAF gene associated with
mation. The high activity mutants signal to ERK by human cancers has identified over 30 single site mis-
directly phosphorylating MEK, whereas the impaired sense mutations, mostly within the kinase domain. The
activity mutants stimulate MEK by activating endoge- mechanism of oncogenic activation of B-RAF therefore
nous C-RAF, possibly via an allosteric or transphos- differs fundamentally from that of v-Raf, a retroviral on-
phorylation mechanism. cogene derived from C-RAF. The constitutive activity
and high transforming potential of v-Raf most likely re-
Introduction sults from loss of the autoinhibitory N-terminal region
combined with targeting to the plasma membrane. Most
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conserved RAS-activated protein kinase cascade that the glycine-rich P loop of the N lobe and the activation
regulates cell growth, proliferation, and differentiation segment and flanking regions. A Glu for Val substitution
in response to growth factors, cytokines, and hormones at residue 599 in the activation segment, adjacent to
the conserved DFG motif, accounts for 90% of B-RAF
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vated, it constitutively stimulates ERK activity in vivo (V599DB-RAF) fold more active than basal WTB-RAF (Figure
1A). We refer to these mutants as the high activity group.independent of RAS, and it potently transforms NIH3T3
cells. Interestingly, the conserved regulatory phosphory- A further eleven mutants had basal kinase activities
some 1.3 (G468EB-RAF) to 64 (L596VB-RAF) fold higher thanlation sites within the activation segment of B-RAF,
Thr598 and Ser601, flank Val599, leading to the sugges- WTB-RAF (Figure 1B), and because their activities were
between basal and G12VRAS-activated WTB-RAF, we refertion that the Glu substitution at this position functions
as a phospho-mimetic (Davies et al., 2002). Analysis of to these mutants as the intermediate activity group. The
activities relative to WTB-RAF we observe are signifi-three other oncogenic mutants of B-RAF showed that
they stimulate kinase activity in a manner similar to cantly higher than those recently published for four of
the mutants (Ikenoue et al., 2003). However, in thatV599EB-RAF (Davies et al., 2002). Intriguingly however,
extensive analysis of B-RAF mutations in cancer shows study, ATP was used at the subphysiological concentra-
tion of 130 M, which may account for their relativelythat seven of the mutations involve highly conserved or
invariant residues in the catalytic domain (Davies et al., low activity.
Next, we examined the ability of these mutants to2002; Yuen et al., 2002) that in other kinases are known
to be required for optimal catalytic activity (Johnson et activate endogenous ERK in COS cells. Western blotting
with an antibody that specifically recognizes the duallyal., 1996; Manning et al., 2002), raising the question of
how these mutants promote tumorigenesis. phosphorylated and active forms of ERK1 and ERK2
indicated that all eighteen mutants stimulate endoge-To investigate the mechanisms by which mutant on-
cogenic forms of B-RAF promote cancer, we have exam- nous ERK in COS cells (Figures 1C and Supplemental
Table S1 online). The high activity mutants stimulatedined a panel of 22 mutants. We show that eighteen
mutants activate B-RAF in vitro and stimulate ERK sig- ERK phosphorylation to a similar level as that stimulated
by G12VRAS, whereas the intermediate activity mutantsnaling in vivo, conforming to the conventional model of
an activating oncogene. However, four mutants have were less efficient at stimulating ERK phosphorylation
(Figure 1C). We used an immunoprecipitation kinasereduced kinase activity in vitro, but surprisingly, three
of these can activate wild-type C-RAF and thereby sig- assay to measure ERK activity directly. G12VRAS activated
ERK by approximately 4-fold (Figure 1D). G465AB-RAF,nal to ERK. We present a crystallographic analysis of
the WTB-RAF and V599EB-RAF kinase domains in complex G468EB-RAF, N580SB-RAF, and V599EB-RAF, whose in vitro
basal kinase activities are between 1.3- and 480-foldwith the C-RAF inhibitor BAY43-9006 (Lyons et al., 2001).
These structures suggest that many of the residues that higher than WTB-RAF activity (Figures 1A and 1B), acti-
vated ERK by 2- to 4.6-fold (Figure 1D). Thus, despiteare mutated in cancer contribute to stabilization of an
inactive conformation of the B-RAF kinase domain. Mu- possessing widely differing in vitro kinase activities, indi-
vidual B-RAF mutants activated ERK to similar levels astation of these residues destabilizes this inactive confor-
mation, promoting the active state. For most mutants, G12VRAS. Finally, several high and intermediate activity
mutants transformed NIH3T3 cells (Supplemental Tablethis stimulates enhanced B-RAF kinase activity toward
MEK. However, a few mutants act through a different S1 on Cell website).
mechanism because although their activity toward MEK
is reduced, they adopt a conformation that activates Three B-RAF Cancer Mutants Have Impaired
wild-type C-RAF, which then signals to ERK. Kinase Activity but Activate ERK in Cells
We identified four cancer-associated B-RAF mutants
whose basal kinase activities were reduced to betweenResults and Discussion
30% and 80% of the activity of WTB-RAF (Figure 2A). We
term these mutants the impaired activity group. Strik-The Majority of Mutant B-RAF Proteins in Human
ingly, however, despite their reduced in vitro kinase ac-Cancer Have Elevated Kinase Activity
tivity, three of the mutants still activated endogenousTo characterize B-RAF mutants, we transiently ex-
ERK in COS cells, although to lower levels than otherpressed them as myc-epitope-tagged fusion proteins in
mutants (Figures 2B and 2C). One mutant, D593VB-RAF,COS cells and measured their in vitro kinase activity.
failed to activate ERK in COS cells and behaved similarlySome of the mutants have an increased Km for ATP
to a mutant (KDB-RAF) in which the catalytic lysine (Lys482)compared to WTB-RAF, resulting in a relative underesti-
is mutated to methionine (Figures 2B and 2C). The threemation of their activity when assayed at subphysiologi-
impaired activity mutants that activate ERK also activatecal concentrations of ATP (Supplemental Figure S2 at
MEK in COS cells (Figure 2D). To further analyze thesehttp://www.cell.com/cgi/content/full/116/6/855/DC1).
mutants in vivo, we expressed them in developing Xeno-However, there was little apparent difference in the
pus embryos and stained for active ERK. WTB-RAF didKm of wild-type and mutant B-RAF for MEK (Supple-
not activate ERK in Xenopus cells, whereas V599EB-RAFmental Figure S3 online). Equivalent amounts of each
and the three impaired activity mutants that activatemutant protein were immunoprecipitated (Supplemental
ERK in COS cells induced strong activation in XenopusFigure S1), and their kinase activity was determined by
cells (Figure 2E). As in COS cells, D593VB-RAF and KDB-RAFmeasuring direct MEK phosphorylation using ATP at a
did not activate ERK in Xenopus cells (Figure 2E).physiological concentration of 5 mM and MEK at 30 M.
Oncogenic RAS (G12VRAS) activates wild-type B-RAF
(WTB-RAF) by95-fold (Figures 1A and 1B, Supplemental Impaired Activity Mutants Stimulate C-RAF In Vivo
One explanation for how impaired activity mutants stim-Table S1 on Cell website). Seven of the mutants had
basal kinase activities that exceeded G12VRAS-stimu- ulate MEK in vivo is that they activate endogenous
C-RAF. Previous studies had demonstrated that C-RAFlated WTB-RAF activity, being 130 (E585KB-RAF) to 700
Mechanism of Oncogenic Activation of B-RAF
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Figure 1. Characterization of Activated Mutant B-RAF Proteins from Human Cancer
The indicated myc-epitope-tagged wild-type and mutant B-RAF proteins were expressed in COS cells and their kinase activity was measured.
Where indicated, G12VRAS (RAS) was included in the transfections. (A) B-RAF kinase activity for high activity mutants. (B) B-RAF kinase activity
for intermediate activity mutants. (C) Western blot of myc-tagged B-RAF, total ERK2, and ppERK in COS cells expressing the high and
intermediate activity mutants. (D) ERK kinase activity in COS cells expressing B-RAF mutant proteins.
and B-RAF form complexes in mammalian cells (Weber COS and Xenopus cells induced strong C-RAF activa-
tion, as did the intermediate activity mutants (Figure 3B).et al., 2001). Consistent with these data, we found that
exogenously expressed WTB-RAF formed a complex WTB-RAF, D593VB-RAF, and KDB-RAF, which do not activate
ERK in COS cells, do not activate C-RAF (Figure 3B).with endogenous C-RAF (Figure 3A). This complex
was not disrupted by G12VRAS, and C-RAF also formed To test whether the high activity mutant V599EB-RAF
can also activate C-RAF, we expressed HA-taggedcomplexes with high (V599EB-RAF), intermediate (G465AB-RAF,
G468EB-RAF), and impaired (G465EB-RAF, G465VB-RAF, C-RAF with myc-tagged V599EB-RAF in COS cells, immu-
noprecipitated C-RAF, and measured its activity. ToG595RB-RAF) activity B-RAF mutants (Figure 3A). Thus the
complexes are not affected by either B-RAF activity or demonstrate that the activity being measured is due to
C-RAF, we show that G465AB-RAF, which activates endog-mutational status. To test whether C-RAF was activated,
we used an antibody to immunoprecipitate C-RAF and enous C-RAF in COS cells (Figure 3B), activates ex-
ogenous WTC-RAF but not KDC-RAF (Figure 3C). Whenmeasured the immunoprecipitates for RAF kinase activ-
ity in a coupled kinase cascade assay at 800 M ATP, V599EB-RAF was coexpressed with WTC-RAF, substantial
RAF kinase activity was observed in the C-RAF im-conditions where intermediate and impaired activity mu-
tants have negligible activity (Supplemental Figure S2 munoprecipitate, but this was reduced by 80% when
KDC-RAF was substituted for WTC-RAF (Figure 3C). Weon Cell website), whereas C-RAF activity remains high
(Mason et al., 1999). Remarkably, the three impaired assume that the residual activity represents the contri-
bution from coimmunoprecipitated V599EB-RAF and con-activity B-RAF mutants that induce ERK activation in
Cell
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Figure 2. Characterization of Impaired Activity B-RAF Mutants
(A) B-RAF kinase activity. (B) ppERK staining in COS cells extracts. (C) ERK kinase activity in COS cell extracts. (D) MEK phosphorylation
in COS cells expressing B-RAF mutants or G12VRAS. (E) ERK activation in Xenopus embryos expressing the indicated B-RAF mutants or
uninjected control.
clude that V599EB-RAF activates C-RAF. Mutant B-RAF C-RAF depletion did not affect ERK activity, whereas
B-RAF depletion blocked ERK activity (Figure 3F). Inproteins were extremely efficient at activating C-RAF,
inducing 5- to 8-fold more activity than was induced by H1666 cells, however, which express the impaired activ-
ity mutant G465VB-RAF (Davies et al., 2002), both B-RAFG12VRAS (Figure 3C).
To provide additional evidence that the impaired ac- and C-RAF are required for ERK activation (Figure 3F).
Thus, although C-RAF is not required for ERK activationtivity B-RAF mutants stimulate ERK activity in vivo
through activation of WTC-RAF, we used an RNA interfer- by either the high or intermediate activity B-RAF mu-
tants, the ability of impaired activity B-RAF mutants toence approach. A C-RAF-specific siRNA oligonucleo-
tide reduced C-RAF protein by 50%–60% compared to stimulate ERK is dependent on C-RAF.
the nonspecific, scrambled control but did not alter the
levels of either B-RAF (Figure 3D) or A-RAF protein (C. Expression, Purification, and Enzyme Activity
of WTB-RAF and V599EB-RAF Kinase DomainsWellbrook and R.M., unpublished data). Depleting
C-RAF had little effect on ERK activity in COS cells To understand how cancer-associated mutations influ-
ence the activity and function of the protein, we de-expressing WTB-RAF, the intermediate activity mutant
G465AB-RAF, or the high activity mutant V599EB-RAF (Fig- termined the crystal structures of the WTB-RAF and
V599EB-RAF kinase domains. We expressed the kinaseures 3D and 3E). In contrast, in COS cells expressing the
impaired activity mutants, C-RAF depletion significantly domain of human B-RAF equivalent to v-Raf using the
baculovirus/insect cell system. B-RAF is a client proteinsuppressed ERK activation (Figure 3E). Similarly, in the
human cancer cell line WM266-4, which expresses the of the Hsp90/p50Cdc37 chaperone (Blagosklonny, 2002;
Stancato et al., 1993), and coexpression of B-RAF withhigh activity mutant V599DB-RAF (Davies et al., 2002),
Mechanism of Oncogenic Activation of B-RAF
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Figure 3. C-RAF Is Required for ERK Activation by the Impaired B-RAF Mutants
(A) B-RAF and C-RAF complex analysis in COS cells. Levels of exogenous B-RAF and endogenous C-RAF are shown in the lower two panels
and B-RAF in the C-RAF IP in the upper panel. Identical results were obtained using two different anti-C-RAF antibodies.
(B) Kinase activity of endogenous C-RAF from COS cells expressing the indicated B-RAF mutant.
(C) The RAF activity in C-RAF immunoprecipitates from COS cells expressing WTC-RAF (WT) or KDC-RAF (KD) together with the indicated
B-RAF constructs.
(D) C-RAF depletion in COS cells. COS cells expressing the B-RAF mutant indicated were treated with C-RAF or scrambled control (SCR)
siRNA oligonucleotides as indicated and the levels of mutant B-RAF, endogenous C-RAF, phosphorylated ERK, and total ERK are shown.
(E) Endogenous ERK kinase activity in COS cells expressing B-RAF mutants and treated with siRNA.
(F) C-RAF depletion in cancer cell lines. WM266-4 and H1666 cells were treated under mock conditions or with the C-RAF, B-RAF, and
scrambled control (SCR) siRNA oligonucleotides as indicated, and the levels of endogenous B-RAF, C-RAF, phosphorylated ERK, and total
ERK are shown.
human p50Cdc37 significantly increased expression levels Using this system, B-RAF was isolated as a complex
with p50Cdc37 and two insect cell proteins, Hsp90 and(data not shown), most likely because endogenous in-
sect cell Hsp90 stabilizes the human B-RAF protein. 14-3-3. The role of 14-3-3 binding to the C terminus
Cell
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of C-RAF is controversial. Some studies suggest that the central phenyl ring of the inhibitor. At the opposite
end of the inhibitor, the lipophilic trifluoromethyl phenylbinding is necessary for activity (Avruch et al., 2001;
ring inserts into a hydrophobic pocket formed betweenKolch, 2000). However, under some conditions, dissoci-
the C and E helices and N-terminal regions of theation of 14-3-3 from C-RAF does not alter its kinase
DFG motif and catalytic loop. The aliphatic side chainsactivity toward MEK in vitro (Michaud et al., 1995), and
of Lys482, Leu513, and Thr528 contact the central phe-14-3-3 binding to the C terminus of B-RAF is not required
nyl ring of the inhibitor. In addition to the van der Waalsfor the ability of B-RAF to phosphorylate MEK in vitro
interactions that dominate B-RAF-inhibitor contacts,but instead couples the kinase to downstream effector
polar interactions also contribute to binding. Impor-complexes (MacNicol et al., 2000). To isolate a more
tantly, the urea group of the inhibitor forms two hydrogenhomogeneous preparation of B-RAF for crystallographic
bonds with the protein, one via its amide nitrogen atomstudies, we expressed a C-terminal truncated form of
to the carboxylate side chain of the catalytic Glu500the kinase that removed the 14-3-3 binding site. This
residue and the second via the carbonyl moiety to theisolated B-RAF kinase domain (termed WTB-RAF) was
main chain nitrogen of Asp593 of the DFG motif. Anseparated from Hsp90/p50Cdc37 during purification and
equivalent constellation of hydrogen bonds contributeswas then dephosphorylated. To analyze the conse-
to the interactions between c-Abl and p38 MAP kinasequence of a Glu substitution for Val599, we also ex-
and their respective inhibitors STI-571 and BIRB-796pressed the kinase domain of V599EB-RAF (V599EB-RAF).
(Nagar et al., 2002; Pargellis et al., 2002; Schindler etThe V599EB-RAF kinase domain was 500-fold more
al., 2000). Finally, the ring nitrogen atom of the pyridylactive than WTB-RAF (data not shown). Thus the Glu
moiety, which enhances affinity some 5-fold comparedsubstitution for Val599 exerts its stimulatory effect on
with a carbon atom (Lowinger et al., 2002), accepts akinase activity within the context of the kinase domain
hydrogen bond from the main chain nitrogen of Cys531of B-RAF, and this suggests that B-RAF activation is
of the interdomain hinge region, whereas the methylnot simply a release from the autoinhibitory restraints
amide side group contacts the main chain carbonyl ofconferred by the N-terminal region. Moreover, because
Cys531.we dephosphorylated the purified B-RAF kinase do-
The structure of B-RAF is markedly reminiscent ofmain, the high activity of V599EB-RAF indicates that acti-
the inactive conformation of the c-Abl tyrosine kinasevation segment phosphorylation is not required for the
domain associated with the inhibitor STI-571 (Gleevec)kinase activity of the mutant protein.
(Figure 5B) (Nagar et al., 2002; Schindler et al., 2000),
and it also shares significant similarities with the p38Overall Structure and B-RAF
MAP kinase-BIRB 796 complex (Pargellis et al., 2002).BAY43-9006 Interactions
There is considerable overlap between the B-RAF andThe crystals that we obtained with the WTB-RAF and
c-Abl inhibitors, and each molecule interacts with theirV599EB-RAF kinase domains alone were not suitable for
cognate kinases in essentially the same way. Specifi-analysis. However, in the presence of the RAF inhibitor
cally, in the two proteins, the relative dispositions of theBAY43-9006, suitable crystals were obtained with both
N and C lobes, C helix, and DFG motif are virtually
preparations. The crystals in the presence of BAY43-
identical. The DFG motif Phe residues in both B-RAF
9006 grew as thin needles with a maximum thickness
and c-Abl (Phe594 in B-RAF) are shifted by some 8 A˚
of 15–20 m and diffracted to resolutions of 2.9 A˚ and
relative to their counterparts in active protein kinases.
3.4 A˚ for WTB-RAF and V599EB-RAF, respectively. Details BAY43-9006 contributes to the inactive conformation of
of the structure determination are described in Experi- the DFG motif both by interacting with the phenyl ring
mental Procedures and Supplemental Table S2 online. of Phe594 and because the trifluoromethyl phenyl moi-
Wild-type and V599EB-RAF kinase domains adopt essen- ety of the inhibitor inserts into the site that Phe594 would
tially identical conformations in the presence of the in- presumably occupy in the active state. Significantly, the
hibitor (rmsd between equivalent C-atoms of 0.64 A˚, structure of the c-Abl STI-571 complex indicates that
Supplemental Figure S4). The protein is well ordered, the STI-571 inhibitor promotes the inactive conformation
except for the N terminus (Gln432–Ser446), and a region of the DFG motif of c-Abl by a similar mechanism.
of the activation segment, residues Lys600–Gln611. In the active conformation of protein kinases, the acti-
The kinase domain of B-RAF adopts the bilobal ar- vation segment adjacent to the DFG motif forms a 
chitecture characteristic of other members of the pro- sheet interaction with the 6 strand. However, in the
tein kinase family (Figure 4). In both wild-type and mu- inactive B-RAF and c-Abl structures, similar to the
tant B-RAF, the BAY43-9006 molecule is well resolved unphosphorylated insulin receptor kinase (Hubbard et
in the electron density maps, with the inhibitor spanning al., 1994), the flipped conformation of the DFG motif
the length of the interfacial cleft, buried deeply between orients this region of the activation segment toward the
the N and C lobes (Figures 4 and 5A). Numerous interac- P loop of the N lobe. Consequently, in B-RAF, residues
tions are formed between the protein and inhibitor, and Gly595–Val599 of the activation segment form an array
residues that contact BAY43-9006 are conserved in of hydrophobic interactions with the P loop residues
C-RAF, consistent with much of the structure-activity Gly463–Val470 (Figure 6A). These interactions, which
relationships of C-RAF inhibition by BAY43-9006 and its comprise the side chains of Leu596 and Val599 of the
derivatives (Lowinger et al., 2002). The distal pyridyl activation segment contacting Gly465, Phe467, and
ring of the inhibitor occupies the ATP adenine binding Val470 of the P loop, function to establish an inactive
pocket, interacting with three aromatic residues: Trp530 conformer of the B-RAF kinase domain, linking the two
of the hinge region, Phe582 at the end of the catalytic regions of the kinase in which the cancer-associated
mutations occur. Apart from the inactive conformationloop, and Phe594 of the DFG motif, which also contacts
Mechanism of Oncogenic Activation of B-RAF
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Figure 4. Structure of WTB-RAF Kinase
Domain
(A) Ribbons diagram of WTB-RAF kinase do-
main in complex with BAY43-9006. The posi-
tions of Asp593 and Phe594 of the DFG motif,
Asn580 of the catalytic loop, and Glu585 are
shown, DFG and APE motif in yellow, rest of
activation segment and the N region are in
red. N lobe is in magenta, C lobe in marine,
and P loop in orange. Residues 600–611 of
the activation loop are disordered (dashed
lines).
(B) Schematic of B-RAF primary structure,
showing functional domains and position of
32 observed cancer-associated mutants of
B-RAF. The amino acid substitutions are
color coded according to their activity class.
Figures were made with PyMOL (http://www.
pymol.org).
of the DFG motif/activation segment, which is not ate activating mutations comprise substitutions of
amino acids that are compatible with catalysis. Suchaligned for ATP and peptide substrate recognition and
mutations either occur at nonconserved positions oris partially disordered, all other key residues of B-RAF
replace conserved residues with amino acids observedrequired for the phosphotransfer reaction are aligned
in other protein kinases (Supplemental Table S1 online).as in active kinases. Specifically, the P loop, which coor-
In contrast, the impaired activity mutants correspond todinates the phosphate and adenine moieties of ATP,
amino acid substitutions of highly conserved/invariantthe catalytic Lys482 and Glu500 of the N lobe and the
residues that are required for an optimal protein kinaseC lobe catalytic loop (Asn580, Arg574, and Asp575) are
catalytic reaction. As discussed below, a unifying fea-all correctly aligned. Therefore only a change in position
ture of oncogenic mutations located in the P loop andof the DFG motif/activation segment is required for con-
DFG motif is the prediction that the inactive conforma-version to the active state.
tion of the DFG motif/activation segment will be destabi-
lized because the hydrophobic cluster linking the DFG
Structural Basis for Activating motif to the P loop is disrupted (Figure 6A). To explain
Oncogenic Mutations the molecular mechanism of B-RAF oncogenic muta-
We have classified cancer-associated mutants of B-RAF tions, we discuss the three classes of mutants in turn,
into high, intermediate, or impaired activity groups ac- and the structural consequences of all mutations are
cording to their ability to stimulate in vitro B-RAF kinase described fully in Supplemental Table S3 online. Here
activity (Figures 1, 2, and 4B, Supplemental Table S1 on we illustrate the principles underlying oncogenic B-RAF
Cell website). Given the phenotypic differences between activation by reference to specific examples.
the various oncogenic mutants, it is striking that nearly Beginning with the high activity mutants, we note that
all mutants (80%) are located within either the P loop all the Val599 mutants belong to this group, as does the
or the activation segment within or adjacent to the DFG neighboring mutant K600E and the P loop mutant G468A
motif (Figure 4B). An apparent paradox of some mutants (Figure 1A). Activating mutants of B-RAF presumably
is that depending on the amino acid substitution, the mimic the conformational changes promoted by activa-
mutant protein has either an elevated or reduced kinase tion segment phosphorylation, and importantly the
V599EB-RAF mutation appears to obviate the requirementactivity (Figure 4B). Significantly, the high and intermedi-
Cell
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Figure 5. Interactions between BAY43-9006 and B-RAF and Comparison with c-Abl Inhibitor Complexes
(A) Stereoview of BAY43-9006 bound to the interdomain cleft of B-RAF. The 2Fo-Fc electron density omit map was calculated from phases
derived from a simulated annealing refinement of the structure omitting the inhibitor. The map is contoured at 1. For clarity, the activation
segment is not shown.
(B) c-Abl-STI-571 and (C) c-Abl-PD173855. The color scheme for B-RAF is the same as Figure 4, c-Abl is cyan. The side chain of the DFG
motif Phe residue is shown for both kinases. In the STI-571 complex, the DFG motif overlaps that of B-RAF.
for activation segment phosphorylation. The structure the wild-type protein, although the side chain of Glu599
is disordered and does not contact the Phe467 sideof the wild-type B-RAF kinase domain indicates that
the aliphatic side chain of Val599 interacts with the phe- chain. The presence of BAY43-9006 presumably re-
strains the DFG motif in the inactive conformation innyl ring of Phe467 in the P loop (Figure 6A). Replacing
the medium sized hydrophobic Val side chain with a V599EB-RAF.
The diverse amino acid substitutions of Val599 capa-larger and charged residue as found in human cancer
(Glu, Asp, Lys, or Arg) would be expected to destabilize ble of activating B-RAF suggest that the mutations all
function by disrupting the inactive conformation. How-the interactions that maintain the DFG motif in an inac-
tive conformation, so flipping the activation segment ever, it is possible that acidic amino acids at position
599 could also interact with Lys506 of the C helix tointo the active position. Consistent with this notion is
the discovery that mutation of Phe467 (F467CB-RAF) also provide additional contacts that promote the active
state (Figure 6B). In the active state of the AGC kinaseoccurs in cancer. In the V599EB-RAF structure, the DFG
motif adopts the same inactive conformation seen in PKB/Akt, Glu299 (equivalent to 599 of B-RAF) contacts
Mechanism of Oncogenic Activation of B-RAF
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Figure 6. Position of Oncogenic Mutants of
B-RAF and Mechanism of Activation by
Thr598 Phosphorylation
(A) The molecular surface generated by the
P loop (residues 463–468) and the DFG motif/
activation segment (residues 593–599) are
colored green and yellow, respectively, dem-
onstrating the hydrophobic cluster created
by the association of the P loop with the DFG
motif, a conformation stabilized by the hydro-
gen bond between the amide side chain of
Asn580 and the main chain amide of Phe594.
(B) A ribbon representation of the structure
of the activation segment of PKB is superim-
posed onto B-RAF, together with the side
chains of Asp293 (Asp593), Lys298 (Thr598),
Glu299 (Val599), Ile301 (Ser601), phos-
phoThr309, and the catalytic Asp275 (Asp575)
and Arg274 (B-RAF residues in parenthesis).
In B-RAF, Glu599 and Glu600 (equivalent to
Glu299 and Glu300 of PKB) could contact
Lys569 of the E helix. Any substitution at
Val599 will be tolerated. The position of Glu600
is modeled from Gly300 of PKB. Structure
of the activation segment is taken from PKB
(Yang et al., 2002). Phosphorylation of Thr598
of B-RAF would position a phosphate group
in the equivalent position as the phosphate
of Thr309 of PKB, allowing interaction with
Arg575 of the B-RAF catalytic loop RD motif.
The equivalent of B-RAF Val599 is a Glu in
PKB, suggesting that in the V599EB-RAF mu-
tant, Glu599 will be solvent exposed and likely
to interact with Lys506 of the C helix.
Arg202 (equivalent to Lys506 of B-RAF) (Yang et al., length B-RAF that relieves N-terminal domain autoinhi-
bition.2002). In support of this notion, Glu and Asp substitu-
tions at position 599 of B-RAF are 2- to 4-fold more Intermediate activating mutants are most likely ex-
plained by their ability to disrupt the inactive conforma-active than the Arg and Lys substitutions (Figure 1A).
Although all four substitutions at position 599 possess tion of the DFG motif; however, the overall kinase activity
is reduced relative to the strongly activating mutantssimilar activity in vitro and in vivo, the Glu substitution
accounts for over 95% of the mutations at this site. It due to suboptimal B-RAF catalytic efficiency. This is best
illustrated by comparing the properties of the stronglyis likely that a Glu mutation occurs at high frequency
because it only requires a single base substitution, activating G468AB-RAF mutant with the intermediate activ-
ity mutant G468EB-RAF, different substitutions of the samerather than the two necessary for conversion to the other
amino acids. Intriguingly, a Glu for Lys substitution at the amino acid which differ 200-fold in their activities (Fig-
ures 1A and 1B, Supplemental Table S1 online). Gly468neighboring position 600 is also a high activity mutant
(Figure 1A). In the wild-type B-RAF kinase domain of the P loop is wedged against Leu596 of the activation
segment and substitutions of Gly468 would thereforestructure, Lys600 is disordered, suggesting that it does
not participate in stabilization of the inactive conforma- perturb P loop-DFG contacts, destabilizing the inacti-
vated state (Figure 6A). The difference in activity be-tion. However, in the active conformation of B-RAF, a
Glu at residue 600 may be positioned to interact with tween G468AB-RAF and G468EB-RAF may be explained by
the observation that in all known protein kinases, onlyLys506 and/or Lys569 of the C and E helices, respec-
tively (Figure 6B). Gly, Ala, or Ser occur at this position (the third Gly resi-
due of the P loop) (Manning et al., 2002) and that an AlaThe only high activity mutant lying outside of the P
loop and DFG motif is E585KB-RAF. Glu585 lies on the for Gly substitution at the equivalent position in PKA
has little influence on PKA activity (Grant et al., 1998).opposite surface of the kinase domain from the DFG
motif (Figure 4A), and it is possible that its mutation We propose that both the Ala and Glu substitutions of
Gly468 of B-RAF share the property of destabilizing thedisrupts potential interdomain interactions within full-
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inactive conformation, but whereas the Ala is permissive obvious from theB-RAF structure how replacing Asp593
would promote the active conformation of the kinase.for high activity, the bulky Glu interferes with P loop/
ATP interactions reducing its potential to elevate ki-
nase activity. Implications for Regulation of B-RAF by Activation
In another example, while replacing Gly463 (the 1st Segment and N Region Phosphorylation
Gly of the P loop) with Val would destabilize the inactive Thr598 is the major activation segment phosphorylation
conformation of the DFG motif, it may also interfere site whereas Ser601 is a relatively minor one (Zhang and
with the optimal interactions between the P loop and Guan, 2000). Substitution of Thr598 with alanine blocks
phosphate groups of ATP. A survey of all human kinase B-RAF activity (Zhang and Guan, 2000), whereas substi-
sequences indicates that Gly is observed in 94% of tution with isoleucine as occurs in cancer strongly acti-
kinases, and only Ala and Ser are also tolerated at this vates B-RAF (Figure 1B). Presumably, the bulky side
position (Manning et al., 2002). Asn580 is a highly con- chain of isoleucine disrupts the inactive conformation
served metal coordinating residue of the catalytic loop of the activation segment, whereas the small Ala side
of the kinase domain. Surprisingly the N580SB-RAF mutant chain does not (Figure 6A). In a similar fashion, we pro-
is 6-fold more active than WTB-RAF. Although Asn580 is pose that phosphorylation of Thr598 would also destabi-
located outside of the P loop and DFG/activation seg- lize the inactive conformation. In addition, by comparing
ment, its replacement by Ser is likely to disrupt the B-RAF to other protein kinases that are regulated by
inactive conformation of the DFG motif. In the inactive activation segment phosphorylation, we suggest that
B-RAF structure, the amide side chain of Asn580 ac- pThr598 provides additional contacts to the conserved
cepts a hydrogen bond from the main chain amide group Arg574 residue adjacent to the catalytic Asp575 of the
of Phe594 of the DFG motif (Figure 6A), indicating that catalytic loop, stabilizing the active form (Johnson et
the Asn580 and Phe594 interactions contribute to the al., 1996) (Figure 6B).
inactive conformation and explaining how mutation of The structure of B-RAF also provides insight into the
either of these residues disrupts the inactive DFG con- role of the regulatory N region. B-RAF is constitutively
formation. The properties of other intermediate mutants phosphorylated on the N region Ser445 within the motif
are listed in Supplemental Table S3 on the Cell website. Ser445-Ser-Asp-Asp448, but the equivalent motif in C-RAF,
The third class of B-RAF oncogenic mutants is the Ser338-Ser-Tyr-Tyr341, is subject to regulatory phosphory-
most surprising because these comprise nonconserva- lation on both Ser338 and Tyr341 (Mason et al., 1999).
tive amino acid substitutions of catalytic site residues In C-RAF, replacing the Tyr residues with Asp mimics
that are required for optimal kinase activity. Although the effects of Tyr341 phosphorylation and substituting
these mutations result in the expected reduction of in the Asp residues in B-RAF suppresses basal and RAS-
vitro B-RAF kinase activity, the activity of ERK is stimu- stimulated kinase activity (Fabian et al., 1993; Mason et
lated in vivo. We propose that the oncogenic potential al., 1999). In our B-RAF structure, Asp447 contacts
of these mutants results from a disruption of the inactive Arg505 of the C helix, suggesting that this interaction
DFG conformation. Experiments described above sug- stabilizes the active conformation, providing a molecular
gest that this conformational change is transmitted to explanation for why this Asp is important for the basal
elevate ERK activity via a cooperative activation of wild- and RAS-stimulated kinase activity of B-RAF. It is less
type C-RAF (and possibly B-RAF; M.J.G. and R.M., un- clear what role Ser445 plays in activating B-RAF. How-
published data) although the mechanism of cooperativ- ever, in our V599EB-RAF protein, Ser445 is unphosphory-
ity is unclear (discussed below). The second Gly of the lated and yet the kinase domain is highly active and
P loop (Gly465 in B-RAF) is invariant in all kinases (Man- (excluding the activation segment) resembles an acti-
ning et al., 2002), suggesting that any substitution of vated kinase. These data suggest that phosphorylation
this residue cannot be readily tolerated. Mutations to of Ser445 (and Ser338 in C-RAF) may relieve constraints
the corresponding residue in PKA are detrimental to imposed by the N terminus.
kinase activity (Grant et al., 1998). However, by analogy
to mutants of the 1st and 3rd Gly residues of the P loop Concluding Remarks
that generate activated B-RAF, we predict that these The discovery that oncogenic activating mutations of
mutations destabilize the inactive conformation of the B-RAF occur in two thirds of malignant melanomas and
DFG motif (Figure 6A). Similarly, within the DFG motif at high frequency in other human cancers confirms the
itself, the introduction of a bulky charged residue at significance of the RAS-RAF-MEK-ERK pathway in pro-
Gly595 in the G595RB-RAF mutant is not compatible with moting tumorigenesis. A significantly high frequency of
the DFG motif in the inactive conformation. mutants cluster to the conserved P loop and DFG motif
Our analysis provides a satisfactory explanation for of the kinase, and we show that a unifying feature of
the prevalence of B-RAF mutations within the P loop these mutants is to destabilize the inactive B-RAF
and DFG motif/activation segment. Such mutations dis- structure, thereby promoting an active conformation.
rupt the inactive conformation of the DFG motif, con- Mutations of Val599 occur in 92% of oncogenic forms
verting the activation segment into the active state, of B-RAF, and V599EB-RAF represents 90% of oncogenic
thereby mimicking its phosphorylation. However, one B-RAF mutants (Supplemental Table S1 online). Inter-
cancer-associated mutant D593VB-RAF behaves differ- estingly, oncogenic activating mutants of c-Kit and Met
ently from the three classes of mutants we have charac- (a Val for Asp substitution; Glover et al., 1995; Kitayama
terized. Significantly, this mutant is almost completely et al., 1995) correspond to Val599 of B-RAF, raising
inactive in vitro and is unable to activate either ERK or the possibility that a related structural mechanism may
underlie oncogenic activation of these tyrosine kinases.C-RAF in vivo. Consistent with these findings, it is not
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Figure 7. Activating and Impaired Activity
B-RAF Mutants Stimulate ERK Signaling
through Distinct Mechanisms
(A) The activated mutants can directly phos-
phorylate and activate MEK and although
they also activate C-RAF, their ability to signal
to ERK does not require this pathway.
(B) The impaired activity B-RAF mutants can-
not stimulate efficient activation of MEK, but
can stimulate C-RAF activity, which then acti-
vates MEK. Their ability to signal to ERK is
therefore dependent on C-RAF protein.
We propose that other activating mutants also destabi- There are various possibilities for how the impaired
activity mutants of B-RAF generate elevated wild-typelize the inactive conformation of the DFG motif, although
it is noteworthy that these mutants constitute on aver- C-RAF and B-RAF activity. First, the presence of the
active conformation of B-RAF sequesters negative in-age 0.3% of B-RAF mutations (Supplemental Table S1
online). Oncogenic mutants of B-RAF also have analo- hibitors of RAF kinases (for example, protein phospha-
tases or the RAF inhibitory protein RKIP; Kolch, 2000).gies with STI-571-resistant mutants of BCR-ABL (Azam
et al., 2003). Two such mutations, situated within the Alternatively, the active conformation may recruit posi-
tive effectors of the pathway that act on wild-type RAFactivation segment (equivalent to Leu596 and Lys600
of B-RAF), are likely to destabilize the inactive conforma- kinases. Finally, the active conformation of B-RAF may
promote the active conformation of C-RAF via an alloste-tion of the DFG/activation segment of the kinase, dis-
rupting the binding site for the drug. ric mechanism or directly phosphorylate the activation
segment of wild-type RAF kinases. The possibility thatOur findings that BAY43-9006 interacts with an inac-
tive conformation of B-RAF would suggest that activat- an autocrine feedback loop activates C-RAF is not con-
sistent with our findings that the MEK inhibitor UO126ing oncogenic mutants of B-RAF would be less sensitive
to the inhibitor than WTB-RAF, with consequent implica- has no effect on the ability of B-RAF mutants to stimulate
C-RAF, whose activity is also independent of RAStions for potential BAY43-9006-induced resistant muta-
tions of the kinase. Consistent with this prediction, (M.J.G. and R.M., unpublished data). It is unlikely that
the lack of activity of these mutants is due to their alteredkinetic studies from BAYER pharmaceuticals have re-
cently shown that V599EB-RAF is 2-fold less sensitive to binding to Hsp90 and 14-3-3 because a recent study
has shown that D593VB-RAF and G595RB-RAF bind theseBAY43-9006 than WTB-RAF (IC50s of 38 and 22 nM, re-
spectively; Brian Schwartz, personal communication). proteins with similar affinity as WTB-RAF (Ikenoue et al.,
2003). An interesting possibility is that communicationWe have also characterized a class of oncogenic mu-
tants that reduce kinase activity relative to WTB-RAF (Fig- between impaired activity mutants of B-RAF and endog-
enous wild-type RAF kinases could be mediated viaure 2). These mutants have weak oncogenic potential
as judged by their inability to transform NIH3T3 cells scaffolding molecules such as KSR1, and it has been
demonstrated previously that C-RAF forms oligomers(Supplemental Table S1 online), which is correlated to
the relatively low level of ERK activation. We present with itself (Luo et al., 1996) and with B-RAF (Weber et al.,
2001), a finding confirmed in our studies. Furthermore,data that impaired activity mutants of B-RAF trigger the
activity of wild-type C-RAF and B-RAF, and our siRNA induced dimerization of C-RAF stimulates ERK activity
(Farrar et al., 1996; Luo et al., 1996). The finding that thestudy demonstrates that the ability of these B-RAF mu-
tants to stimulate ERK is dependent on WTC-RAF. Cru- active conformation of B-RAF is sufficient to stimulate
endogenous wild-type RAF and ERK represents a novelcially, these mutations are predicted to induce an active
kinase conformation. It is this property of the impaired paradigm for the action of an oncogene.
activity mutants that may explain their ability to activate
ERK via C-RAF even though their kinase activity toward Experimental Procedures
MEK is severely impaired. However, D593VB-RAF and the
kinase dead mutant K482MB-RAF, which we predict would Mammalian Cell Expression
Details of the expression constructs for G12VRAS, C-RAF, and B-RAF,not promote the active state, do not induce either ERK
COS cell transfection conditions, NIH3T3 cell transformation assays,or C-RAF activity. We propose that whereas the high
Western blotting, protein expression measurements, and the RAF-activity B-RAF mutants primarily stimulate ERK via di-
coupled kinase assay have all been described (Marais et al., 1997,
rect MEK phosphorylation, the impaired activity mu- 1998; Mason et al., 1999). Details of the MEK phosphorylation assay
tants, which are defective in direct MEK phosphoryla- are provided in the Supplemental Data online. B-RAF mutants were
generated using PCR mutagenesis and vector sequence verifiedtion, induce ERK by triggering C-RAF activity (Figure 7).
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using automated dideoxy sequencing. The human cancer cell lines by Cancer Research-UK, Institute of Cancer Research, and Well-
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